KannaLife Sciences, a Medical Marijuana Inc (OTCMKTS:MJNA)’s portfolio company, holds a front line position in developing cannabinoid based therapeutics and other novel health care related offerings for the public. The company disclosed that KannaLife Sciences was the topic of extensive interviews in the making of the CNN’s documentary series “Weed 3: The Marijuana Revolution.”
The program that was aired on last Sunday interviewed several cannabis science leaders. It also included the Mr. Dean Petkanas who is the CEO of Medical Marijuana’s portfolio company KannaLife Sciences. When question about the company’s CBD-based research and advancement measures, Mr. Petkanas answered to Dr. Sanjay Gupta that hopefully they can interfere in the process of late-stage neurodegeneration and defer the process.
KannaLife Sciences, the portfolio firm of Medical Marijuana is a late-stage biotechnology development firm currently in pharmaceutical advancement of novel therapeutic agents formulated for neuro-modulation and neuro-protection. It holds two license deals with the National Institutes of Health to use the US Government Patent on the therapeutic use of cannabinoids, derived from the cannabis crop family i.e. industrial hemp or marijuana. It is involved in an ongoing research at the Pennsylvania Biotechnology Center for target drug candidates to cure Hepatic Encephalopathy and Chronic Traumatic Encephalopathy. Both are oxidative stress problems that affect behavioral and cognitive function.
The expert view
Medical Marijuana Inc (OTCMKTS:MJNA) along with General Hemp, LLC and PhytoSphere Systems are the main investors in KannaLife Sciences’ Series A financing round. The company’s CEO, Stuart W. Titus said that having been a member of KannaLife board for many years now, he is excited to see that the company is receiving deserved attention by the media. In last trading session, the stock price of Medical Marijuana surged more than 1% to close the trading session at $0.0890. The gains came at a share volume of 3.03 million compared to average volume of 3.49 million.